Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).
Chris Parker(Royal Marsden NHS Foundation Trust), Emma Hall(Institute of Cancer Research), Sue Chua(Royal Marsden NHS Foundation Trust), John Staffurth(Velindre NHS Trust), Gary Cook(Guy's Hospital), David Dolling(Institute of Cancer Research), Dow‐Mu Koh(Royal Marsden NHS Foundation Trust), Penelope Flohr(Royal Marsden NHS Foundation Trust), Alison Tree(Royal Marsden NHS Foundation Trust), Anwar R. Padhani(Mount Vernon Cancer Centre), Angus Robinson(Royal Sussex County Hospital), Sophie Perry(Institute of Cancer Research), Bernadette Johnson(Royal Marsden NHS Foundation Trust), Peter Chatfield(Institute of Cancer Research), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Roberto Alonzi(Mount Vernon Cancer Centre), Jessica Finch(Mount Vernon Cancer Centre), Yong Du(Royal Marsden Hospital), Nina Tunariu(Leicester Royal Infirmary), Matthew Blackledge(Institute of Cancer Research)
Cited by 2
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k